EXACT Sciences Corp. (EXAS)

103.97
NASDAQ : Health Technology
Prev Close 103.40
Day Low/High 100.59 / 104.73
52 Wk Low/High 53.06 / 123.99
Avg Volume 1.53M
Exchange NASDAQ
Shares Outstanding 129.49M
Market Cap 13.39B
EPS -1.40
P/E Ratio N/A
Div & Yield N.A. (N.A)
Exact Sciences Aims To Collaborate With City Of Madison & University Of Wisconsin In Developing A Biotech Campus

Exact Sciences Aims To Collaborate With City Of Madison & University Of Wisconsin In Developing A Biotech Campus

Exact Sciences Corp. (NASDAQ: EXAS) announced today that it will continue collaborating with the City of Madison in an attempt to establish a headquarters in Madison and is in discussions with the University of...

Exact (EXAS) Highlighted As Today's Perilous Reversal Stock

Exact (EXAS) Highlighted As Today's Perilous Reversal Stock

Trade-Ideas LLC identified Exact (EXAS) as a "perilous reversal" (up big yesterday but down big today) candidate

Exact (EXAS) Showing Signs Of Being Water-Logged And Getting Wetter

Exact (EXAS) Showing Signs Of Being Water-Logged And Getting Wetter

Trade-Ideas LLC identified Exact (EXAS) as a "water-logged and getting wetter" (weak stocks crossing below support with today's range greater than 200%) candidate

Cologuard® Growth Trajectory Increases To 34,000 Completed Tests, Generates $12.6M In Revenue In Third Quarter 2015

Cologuard® Growth Trajectory Increases To 34,000 Completed Tests, Generates $12.6M In Revenue In Third Quarter 2015

Exact Sciences Corp. (Nasdaq:EXAS) today announced that the company continued its strong performance during the third quarter ended Sept.

New Study Bolsters Cologuard's Performance In Detecting Colorectal Cancer And Ability To Improve Access To Screening (Photo: Business Wire)

New Study Bolsters Cologuard's Performance In Detecting Colorectal Cancer And Ability To Improve Access To Screening (Photo: Business Wire)

Exact Sciences Corp. (NASDAQ: EXAS) today announced that a new peer-reviewed study of Cologuard®, a multi-target stool DNA test (MT-sDNA), confirms its performance across all stages of colorectal cancer and...

Today's Dead Cat Bounce Stock Is Exact (EXAS)

Today's Dead Cat Bounce Stock Is Exact (EXAS)

Trade-Ideas LLC identified Exact (EXAS) as a "dead cat bounce" (down big yesterday but up big today) candidate

Interesting EXAS Put And Call Options For December 18th

Interesting EXAS Put And Call Options For December 18th

Investors in EXACT Sciences Corp. saw new options become available this week, for the December 18th expiration.

Exact (EXAS) In A Perilous Reversal

Exact (EXAS) In A Perilous Reversal

Trade-Ideas LLC identified Exact (EXAS) as a "perilous reversal" (up big yesterday but down big today) candidate

Stool DNA Screening Technology To Be Featured At ACG 2015

Stool DNA Screening Technology To Be Featured At ACG 2015

Exact Sciences Corp. (NASDAQ: EXAS) today announced that data supporting its stool DNA (sDNA) screening platform for colorectal cancer will be presented in three posters at the American College of Gastroenterology's...

Exact Sciences To Host Third-quarter 2015 Results Webcast And Call

Exact Sciences To Host Third-quarter 2015 Results Webcast And Call

Exact Sciences Corp. (Nasdaq: EXAS) today announced that the company will host a webcast and conference call on Oct.

Exact (EXAS) Is Today's Dead Cat Bounce Stock

Exact (EXAS) Is Today's Dead Cat Bounce Stock

Trade-Ideas LLC identified Exact (EXAS) as a "dead cat bounce" (down big yesterday but up big today) candidate

Another reason US healthcare costs are soaring

Another reason US healthcare costs are soaring

Americans are being asked to pay more for non-invasive screening.

Trade-Ideas: Exact (EXAS) Is Today's Weak On High Relative Volume Stock

Trade-Ideas: Exact (EXAS) Is Today's Weak On High Relative Volume Stock

Trade-Ideas LLC identified Exact (EXAS) as a weak on high relative volume candidate

Today's Dead Cat Bounce Stock Is Exact (EXAS)

Today's Dead Cat Bounce Stock Is Exact (EXAS)

Trade-Ideas LLC identified Exact (EXAS) as a "dead cat bounce" (down big yesterday but up big today) candidate

Are Drug Stocks What's Ailing the Market?

This move in health care takes your breath away.

Battleground: Analysts Differ On Exact Sciences Amid Stock Plunge

Battleground: Analysts Differ On Exact Sciences Amid Stock Plunge

Shares of Exact Sciences are tumbling 40% after regulators issued preliminary guidelines identifying the company's main product as "an alternative screening test" that can be used in "select clinical circumstances."

Exact Sciences Tumbles on Colon Cancer Screening Snub

Exact Sciences Tumbles on Colon Cancer Screening Snub

An independent panel of health care experts did not include Exact Sciences' Cologuard on a draft list of recommended colon cancer screening tests in the U.S.

Exact (EXAS): Heavy Pre-Market Activity

Exact (EXAS): Heavy Pre-Market Activity

Trade-Ideas LLC identified Exact (EXAS) as a pre-market mover with heavy volume candidate

Exact Sciences To Host Webcast And Conference Call Regarding U.S. Preventive Services Task Force Draft Recommendations

Exact Sciences To Host Webcast And Conference Call Regarding U.S. Preventive Services Task Force Draft Recommendations

Exact Sciences Corp. (Nasdaq: EXAS) today announced that the company will host a webcast and conference call to discuss the U.

Cologuard® Included As Alternative Screening Test Under Draft USPSTF Guidelines

Cologuard® Included As Alternative Screening Test Under Draft USPSTF Guidelines

Exact Sciences (Nasdaq: EXAS) issued the following statement today following the U.

Strong On High Volume: Exact (EXAS)

Strong On High Volume: Exact (EXAS)

Trade-Ideas LLC identified Exact (EXAS) as a strong on high relative volume candidate

CMS Issues Preliminary Determination Maintaining Cologuard® Reimbursement Rate

CMS Issues Preliminary Determination Maintaining Cologuard® Reimbursement Rate

Exact Sciences Corp. (Nasdaq: EXAS) today announced that the Centers for Medicare and Medicaid Services (CMS) issued a preliminary determination maintaining the current reimbursement rate for Cologuard, the company's...

Exact Sciences To Participate In Economist's Health Care Forum

Exact Sciences To Participate In Economist's Health Care Forum

Exact Sciences Corp. (Nasdaq: EXAS) today announced that Kevin Conroy, the company's chairman and chief executive, will participate in The Economist's Health Care Forum: War on Cancer on Sept.

'Mad Money' Lightning Round: Consolidated Edison Is Great

'Mad Money' Lightning Round: Consolidated Edison Is Great

Cramer says the selloff in Lululemon was overdone but be careful on Northern Tier Energy.

Jim Cramer's 'Mad Money' Recap: Why Is This Market So Irrational?

Jim Cramer's 'Mad Money' Recap: Why Is This Market So Irrational?

What's going on in banking, housing, energy and biotechs has Cramer raising a red flag.

January 2018 Options Now Available For EXACT Sciences Corp.

January 2018 Options Now Available For EXACT Sciences Corp.

Investors in EXACT Sciences Corp. saw new options become available today, for the January 2018 expiration.

Exact Sciences Announces Blue Cross Blue Shield Of Rhode Island To Cover Cologuard®

Exact Sciences Announces Blue Cross Blue Shield Of Rhode Island To Cover Cologuard®

Exact Sciences Corp. (NASDAQ: EXAS) today announced that it has entered into an agreement with Blue Cross Blue Shield (BCBS) of Rhode Island, one of the state's leading health plans with more than 500,000 members, to...

In choppy markets short positions add flexibility

In choppy markets short positions add flexibility

Short positions provide portfolio benefits in down markets.

Exact Sciences To Participate In Baird Healthcare Conference

Exact Sciences To Participate In Baird Healthcare Conference

Exact Sciences Corp. (Nasdaq: EXAS) today announced that the company will participate in the Baird 2015 Healthcare Conference in September.

Exact Sciences Highlights CMS Advisory Panel's Unanimous Vote To Maintain Medicare Reimbursement Rate For Cologuard®

Exact Sciences Highlights CMS Advisory Panel's Unanimous Vote To Maintain Medicare Reimbursement Rate For Cologuard®

Exact Sciences Corp. (NASDAQ: EXAS) today announced that the Centers for Medicare and Medicaid Services (CMS) Advisory Panel on Clinical Diagnostic Laboratory Tests voted unanimously to maintain Medicare's current crosswalk...

TheStreet Quant Rating: C- (Hold)